Abstract
Early detection of ovarian cancer might substantially improve results of therapy. After careful surgical staging, 90% of patients with stage I disease and 70% of patients with stage II disease can be cured with currently available therapy. Epithelial ovarian cancer may be one of the malignancies that lends itself to early detection with a blood test. Antigens shed from the ovarian surface into the peritoneal cavity are taken up by diaphragmatic lymphatics and pass through the alternative thoracic duct into the venous circulation. In early work by Knauf and Urbach [1] the OCA antigen could be detected in 70% of patients with early stage disease. OCA was also found in approximately 10% of healthy individuals, precluding its use in screening. This observation did, however, suggest that shed tumor products could be found in the circulation in an early stage of disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Knauf, S. and Urbach, G.I. (1980) A study of ovarian cancer patients using a radioimmunoassay for human ovarian tumorassociated antigen OCA. Am. J. Obstet. Gynecol., 138,1222–3.
Bast, R.C. Jr., Klug, T.L., St John, E. et al., (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 309, 883–7.
Bast, R.C. Jr., Siegal, P.P., Runowicz, C. et al., (1985) Elevation of serum CA 125 prior to diagnosis of epithelial ovarian carcinoma. Gynecol. Oncol., 22,115–20.
Zurawski, V.R. Jr., Orjaseter, H., Andersen, A. and Jellum, E. (1988) Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer, 42, 677–80.
Jacobs, I. and Bast, R.C. Jr. (1989) The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod., 4,1–12.
Einhorn, N., Sjovall, K., Knapp, R.C. et al, (1992) Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet. Gynecol., 80,14–18.
Ramakrishnan, S., Xu, F.J., Brandt, S.J. et al, (1989) Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J. Clin. Invest., 83, 921–6.
Xu, F.J., Ramakrishnan, S., Daly, L. et al, (1991) Increased serum levels of macrophage colony- stimulating factor in ovarian cancer. Am. J. Obstet. Gynecol., 165,1356–62.
Xu, F.J., Yu, Y.H., Li, B.Y. et al, (1991) Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. Cancer Res., 51, 4012–19.
Xu, F.J., Yu, Y.A., Daly, L. et al, (1993) The OVXl radioimmunoassay complements CA 125 for predicting the presence of residual ovarian carcinoma at second look surgical surveillance procedures. J. Clin. Oncol., 11, 1506–10.
Woolas, R.P., Xu, F.J., Jacobs, I.J.et al, (1993) Elevation of multiple serum markers in stage I ovarian cancer. J. Natl Cancer Inst., in press.
Jacobs, L, Prys Davies, A. and Oram, D. (1992) Role of CA-125 in screening for ovarian cancer. In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds P. Sharp, W.P. Mason and W. Creasman), Chapman & Hall, London, pp. 265–76.
Woolas, R., Jacobs, I.J., Xu, F.J. et al, (1993) Serum levels of CA 125, M-CSP and OVXl in stage I and preclinical ovarian cancer. Proc. Am. Sac. Clin. Oncol., 12,110.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Chapman & Hall
About this chapter
Cite this chapter
Bast, R.C. et al. (1995). Complementary and coordinate markers for detection of epithelial ovarian cancers. In: Sharp, F., Mason, P., Blackett, T., Berek, J. (eds) Ovarian Cancer 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0136-4_19
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0136-4_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0138-8
Online ISBN: 978-1-4757-0136-4
eBook Packages: Springer Book Archive